Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
21 December 2021Website:
http://www.allarity.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | 91 min agoDividend
Analysts recommendations
Institutional Ownership
ALLR Latest News
Allarity Therapeutics stock is increasing on Friday with significant pre-market trading, following the company's announcement of a prospectus supplement.
Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at Biomarkers 2024.
Allarity Therapeutics (NASDAQ: ALLR ) stock is taking off on Tuesday after the clinical-stage biopharmaceutical company released data from a Phase 2 clinical trial of stenoparib. That clinical trial saw the company testing the effectiveness of stenoparib in women with advanced ovarian cancer.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Shares of clinical-stage precision medicine company Allarity Therapeutics (NASDAQ: ALLR ) initially soared to a 60% gain for the midweek session before paring down gains to roughly 30%. Undergirding sentiment was early-stage data evaluating the efficacy of Ixempra — a metastatic breast cancer therapeutic — at multiple sites in Europe.
Allarity Therapeutics (NASDAQ: ALLR ) stock is falling hard on Wednesday after the clinical-stage pharmaceutical company launched a public offering. That public offering has the company selling up to $20 million in shares, as well as warrants to purchase its stock.
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform as well as scientists hope.
Shares of Allarity Therapeutics Inc. ALLR, -4.51% plunged 17% in premarket trading on Tuesday after the company told investors that it's struggled to enroll enough patients in Phase 2 studies for Ixempra and senoparib, citing the impact of the pandemic on staffing for clinical-trial sites. The company is testing Ixempra as a treatment for metastatic breast cancer and stenoparib for ovarian cancer.
Allarity Therapeutics announced that it intends to effect a reverse stock split of its common stock, at a ratio of 1 post-split share for every 35 pre-split shares. The post Allarity Therapeutics: 1:35 Reverse Stock Split Goes Into Effect appeared first on Pulse 2.0.
Allarity Therapeutics (NASDAQ: ALLR ) stock is sliding lower on Friday after announcing a reverse stock split. According to a press release, the company plans to enact a one-for-35 reverse stock split.
What type of business is Allarity Therapeutics?
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
What sector is Allarity Therapeutics in?
Allarity Therapeutics is in the Healthcare sector
What industry is Allarity Therapeutics in?
Allarity Therapeutics is in the Biotechnology industry
What country is Allarity Therapeutics from?
Allarity Therapeutics is headquartered in United States
When did Allarity Therapeutics go public?
Allarity Therapeutics initial public offering (IPO) was on 21 December 2021
What is Allarity Therapeutics website?
https://www.allarity.com
Is Allarity Therapeutics in the S&P 500?
No, Allarity Therapeutics is not included in the S&P 500 index
Is Allarity Therapeutics in the NASDAQ 100?
No, Allarity Therapeutics is not included in the NASDAQ 100 index
Is Allarity Therapeutics in the Dow Jones?
No, Allarity Therapeutics is not included in the Dow Jones index
When does Allarity Therapeutics report earnings?
Next earnings report date is not announced yet